CAS: 64248-56-2; 2-Bromo-1,3-Difluorobenzene

上下游产品

CAS号372-18-9 1,3-二氟苯 | CAS号5509-65-9 2,6-二氟苯胺 | CAS号133117-48-3 1,3-difluoro-2-... | CAS号385-00-2 2,6-二氟苯甲酸 | CAS号348-57-2 2,4-二氟溴苯 | CAS号372-18-9 1,3-二氟苯 | CAS号590-17-0 溴乙腈 | CAS号108-86-1 溴苯 | CAS号2285-29-2 1,3-difluoro-2-... | CAS号146355-09-1 tris(2,6-difluo... | CAS号385-00-2 2,6-二氟苯甲酸 | CAS号443-81-2 2-溴-3-氟苯酚 | CAS号35367-38-5 氟脲杀 | CAS号267006-31-5 Borane, (2,6-di...

1,3-二氟苯置于正丁基锂,溴体系中,用 四氢呋喃 作为反应溶剂,化学反应生成 1-溴-2,6-二氟苯
参考文献:3-卤代苯炔的形成:溶剂效应和环加成加合物.
标题:3-卤代苯炔的形成:溶剂效应和环加成加合物.
摘要:非配位溶剂允许在环戊二烯存在下由二卤代和三卤代苯前体通过卤素金属交换诱导形成苯炔(芳烃),从而反应生成1,4-二氢-1,4-甲基-萘.对混合卤化物前体和非酸性diels-Alder二烯陷阱的研究表明,醚和烃类溶剂会影响卤化物的离去基团,从而逆转3-卤代苯炔的区域选择性.
DOI:10.1021/ol049655L

专利信息

专利号:US-11401277-B2
优先权日:2017-11-29
标 题 :Anti-bacterial heterocyclic compounds and their synthesis
发明人：PEER MOHAMED SHAHUL HAMEED; BHARATHAM NAGAKUMAR; KATAGIHALLIMATH NAINESH; SHARMA SREEVALLI; NANDISHAIAH RADHA; RAMACHANDRAN VASANTHI
权利人:BUGWORKS RES INC
摘要:The invention relates to compounds of Formula I and Formula (B) along with their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms, and pharmaceutically active derivatives thereof. These compounds are useful for killing or inhibiting the growth of a microorganism selected from the group consisting of bacteria, virus, fungi, and protozoa.

专利号:TW-200412946-A
优先权日:2002-11-29
标题 :Synthesis of pyrrolidine derivatives and their salts

专利号:US-7615634-B2
优先权日:2003-02-10
标题:4-aminopyrimidine-5-one derivatives
发明人：BARTKOVITZ DAVID JOSEPH; CHU XIN-JIE; DING QINGJIE; JIANG NAN; LOVEY ALLEN JOHN; MOLITERNI JOHN ANTHONY; MULLIN JR JOHN GUILFOYLE; VU BINH THANH; WOVKULICH PETER MICHAEL
权利人:HOFFMANN LA ROCHE
摘要:Novel intermediate compounds are disclosed. These compounds are useful in the synthesis of 4-aminopyrimidine-5-one derivatives that inhibit cyclin-dependent kinases, in particular cyclin-dependent kinase 4 (Cdk4). The 4-aminopyrimidine-5-one derivatives and their pharmaceutically acceptable salts have antiproliferative activity and are useful in the treatment or control of cancer, in particular solid tumors.

专利号:CN-115368239-A
优先权日:2022-09-01
标题:Synthesis of cinnamate derivative and pharmaceutical application thereof

专利号:US-10912780-B2
优先权日:2017-06-08
标题:Heterocyclic compounds useful as anti-bacterial agents and method for production thereof
发明人：PEER MOHAMED SHAHUL HAMEED; BHARATHAM NAGAKUMAR; KATAGIHALLIMATH NAINESH; SHARMA SREEVALLI; NANDISHAIAH RADHA; RAMACHANDRAN VASANTHI; VENKATARAMAN BALASUBRAMANIAN
权利人:BUGWORKS RES INC
摘要:The present disclosure relates to compounds of Formula I, or their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivatives thereof, and pharmaceutical compositions containing them as the active ingredient which can be used as medicaments. The aforementioned substances can also be used in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by microbes. The present disclosure also relates to the synthesis and characterization of aforementioned substances.

专利号:US-8378104-B2
优先权日:2010-02-11
标 题 :7-aminofuropyridine derivatives
发明人：HORNBERGER KEITH R; BERGER DAN M; CHEN XIN; CREW ANDREW P; DONG HANQING; KLEINBERG ANDREW; LI AN-HU; MA LIFU; MULVIHILL MARK J; PANICKER BIJOY; SIU KAM W; STEINIG ARNO G; TARRANT JAMES G; WANG JING; WENG QINGHUA; SANGEM RAJARAM; GUPTA RAMESH C
权利人:OSI PHARMACEUTICALS LLC; HORNBERGER KEITH R; BERGER DAN M; CHEN XIN; CREW ANDREW P; DONG HANQING; KLEINBERG ANDREW; LI AN-HU; MA LIFU; MULVIHILL MARK J; PANICKER BIJOY; SIU KAM W; STEINIG ARNO G; TARRANT JAMES G; WANG JING; WENG QINGHUA; SANGEM RAJARAM; GUPTA RAMESH C
摘要:Compounds of Formula 1, as shown below and defined herein: n n n n n n n n n n n n pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven at least in part by TAK1 or for which an appropriate TAK1 inhibitor is effective. This Abstract is not limiting of the invention.